Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data With Applications to Cancer Clinical Trials

ABSTRACT Joint models for longitudinal and survival data are routinely used in clinical trials or other studies to assess a treatment effect while accounting for longitudinal measures such as patient-reported outcomes. In the Bayesian framework, the deviance information criterion (DIC) and the logarithm of the pseudo-marginal likelihood (LPML) are two well-known Bayesian criteria for comparing joint models. However, these criteria do not provide separate assessments of each component of the joint model. In this article, we develop a novel decomposition of DIC and LPML to assess the fit of the longitudinal and survival components of the joint model, separately. Based on this decomposition, we then propose new Bayesian model assessment criteria, namely, ΔDIC and ΔLPML, to determine the importance and contribution of the longitudinal (survival) data to the model fit of the survival (longitudinal) data. Moreover, we develop an efficient Monte Carlo method for computing the conditional predictive ordinate statistics in the joint modeling setting. A simulation study is conducted to examine the empirical performance of the proposed criteria and the proposed methodology is further applied to a case study in mesothelioma. Supplementary materials for this article are available online.

[1]  John Bryant,et al.  Bayesian Model Specification , 2018, Bayesian Demographic Estimation and Forecasting.

[2]  Joseph Boudreau,et al.  Monte Carlo Methods , 2018, Randomization, Bootstrap and Monte Carlo Methods in Biology.

[3]  Gang Li,et al.  Joint Modeling of Longitudinal and Time-to-Event Data , 2016 .

[4]  Wei Shen,et al.  JMFit: A SAS Macro for Joint Models of Longitudinal and Survival Data. , 2016, Journal of statistical software.

[5]  K. Abrams,et al.  Joint Modeling of Longitudinal and Survival Data , 2016 .

[6]  John L. Perry,et al.  Assessing Model Fit: Caveats and Recommendations for Confirmatory Factor Analysis and Exploratory Structural Equation Modeling , 2015 .

[7]  Wei Shen,et al.  Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials , 2014, Statistics in medicine.

[8]  B. Movsas,et al.  Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Arti Shukla,et al.  Malignant Mesothelioma: Development to Therapy , 2014, Journal of cellular biochemistry.

[10]  Ari Gnanasakthy,et al.  Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  Maral Saadati,et al.  Joint Models for Longitudinal and Time-to-Event Data with Applications in R. Dimitris Rizopoulos (2012). Boca Raton: Chapman & Hall/CRC Texts in Statistical Science Series. 261 pages, ISBN: 978-1439872864. , 2013 .

[12]  Michael J. Crowther,et al.  STJM11: Stata module to fit shared parameter joint models of longitudinal and survival data , 2012 .

[13]  John F P Bridges,et al.  Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. , 2012, Lung cancer.

[14]  D. Rizopoulos Event Time Event Time , 2012 .

[15]  Dimitris Rizopoulos,et al.  Joint Models for Longitudinal and Time-to-Event Data: With Applications in R , 2012 .

[16]  Ping Wang,et al.  Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial , 2012, Health Services and Outcomes Research Methodology.

[17]  Bradley P. Carlin,et al.  Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros , 2012 .

[18]  Peter J. Diggle,et al.  joineR: Joint modelling of repeated measurements and time-to-event data , 2012 .

[19]  Bradley P Carlin,et al.  Joint Modeling of Multiple Longitudinal Patient-Reported Outcomes and Survival , 2011, Journal of biopharmaceutical statistics.

[20]  Joseph G Ibrahim,et al.  Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Pennifer Erickson,et al.  Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  Yueh-Yun Chi,et al.  Bayesian approaches to joint longitudinal and survival models accommodating both zero and nonzero cure fractions , 2007 .

[23]  U. S. D. O. H. A. H. S. F. C. Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[24]  Joseph G Ibrahim,et al.  Joint Models for Multivariate Longitudinal and Multivariate Survival Data , 2006, Biometrics.

[25]  J. Ibrahim,et al.  A Flexible B‐Spline Model for Multiple Longitudinal Biomarkers and Survival , 2005, Biometrics.

[26]  Joseph G. Ibrahim,et al.  Bayesian Survival Analysis , 2004 .

[27]  Joseph G. Ibrahim,et al.  A new joint model for longitudinal and survival data with a cure fraction , 2004 .

[28]  Joseph G. Ibrahim,et al.  BAYESIAN METHODS FOR JOINT MODELING OF LONGITUDINAL AND SURVIVAL DATA WITH APPLICATIONS TO CANCER VACCINE TRIALS , 2004 .

[29]  Joseph G Ibrahim,et al.  Bayesian Approaches to Joint Cure‐Rate and Longitudinal Models with Applications to Cancer Vaccine Trials , 2003, Biometrics.

[30]  U. Gatzemeier,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Marie Davidian,et al.  An estimator for the proportional hazards model with multiple longitudinal covariates measured with error. , 2002, Biostatistics.

[32]  H. Sandler,et al.  The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure. , 2002, Biostatistics.

[33]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[34]  W. Michael Conklin,et al.  Monte Carlo Methods in Bayesian Computation , 2001, Technometrics.

[35]  S L Zeger,et al.  The Evaluation of Multiple Surrogate Endpoints , 2001, Biometrics.

[36]  R Henderson,et al.  Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.

[37]  N. Laird,et al.  Mixture models for the joint distribution of repeated measures and event times. , 1997, Statistics in medicine.

[38]  V. DeGruttola,et al.  Models for empirical Bayes estimators of longitudinal CD4 counts. , 1996, Statistics in medicine.

[39]  S. Chib Marginal Likelihood from the Gibbs Output , 1995 .

[40]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[41]  V. De Gruttola,et al.  Modelling progression of CD4-lymphocyte count and its relationship to survival time. , 1994, Biometrics.

[42]  Ming-Hui Chen Importance-Weighted Marginal Bayesian Posterior Density Estimation , 1994 .

[43]  A. Gelfand,et al.  Bayesian Model Choice: Asymptotics and Exact Calculations , 1994 .

[44]  Yudi Pawitan,et al.  Modeling Disease Marker Processes in AIDS , 1993 .

[45]  J. Geweke,et al.  Bayesian Inference in Econometric Models Using Monte Carlo Integration , 1989 .

[46]  S. Geisser,et al.  A Predictive Approach to Model Selection , 1979 .

[47]  J. Meigs,et al.  WHO Technical Report , 1954, The Yale Journal of Biology and Medicine.

[48]  Berkeley California Disclaimer,et al.  University of California , 1886, The American journal of dental science.

[49]  Joseph G. Ibrahim,et al.  Assessment of Fit in Longitudinal Data for Joint Models with Applications to Cancer Clinical Trials , 2015 .

[50]  J. Ibrahim,et al.  Handbook of survival analysis , 2014 .

[51]  Joseph Hilbe,et al.  Assessment of Fit , 2014 .

[52]  C. Legrand Joint Modeling , 2012, Advanced Survival Models.

[53]  F. Ongaro JOINT MODELS FOR LONGITUDINAL AND TIME-TO-EVENT DATA. A STUDY OF THE INFLUENCE OF THE ASSOCIATION STRUCTURE ON EXPECTED SURVIVAL PROBABILITIES. , 2012 .

[54]  Wesley O Johnson,et al.  Predictive comparison of joint longitudinal-survival modeling: a case study illustrating competing approaches , 2011, Lifetime data analysis.

[55]  Jeremy M G Taylor,et al.  Discussion of “Predictive Comparison of Joint Longitudinal-Survival Modeling: A Case Study Illustrating Competing Approaches”, by Hanson, Branscum and Johnson , 2011, Lifetime data analysis.

[56]  James J. Rusthoven,et al.  Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso , 2005, Supportive Care in Cancer.

[57]  M. Davidian,et al.  Joint modelling of longitudinal and time-to-event data: an overview , 2004 .

[58]  S. Zeger,et al.  Joint analysis of longitudinal data comprising repeated measures and times to events , 2001 .

[59]  M D Schluchter,et al.  Methods for the analysis of informatively censored longitudinal data. , 1992, Statistics in medicine.

[60]  Bruce W. Schmeiser,et al.  Overlapping batch means: something for nothing? , 1984, WSC '84.